Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Richard S. Ginsberg"'
Autor:
Yaela Baine, David M. Koelle, Richard S. Ginsberg, Christine M. Posavad, Terry J. Higgins, Richard B. Ciccarelli, Ashok Cattamanchi, Anna Wald, Jennifer Moses, Lawrence Corey
Publikováno v:
Clinical and Vaccine Immunology. 15:1638-1643
We conducted a double-blind, vehicle-controlled, dose escalation safety and immunogenicity trial of a candidate herpes simplex virus type 2 (HSV-2) surface glycoprotein D2 (gD2) DNA vaccine administered by use of a needle-free device. Sixty-two healt
Autor:
Yaela Baine, David B. Weiner, Richard B. Ciccarelli, Richard S. Ginsberg, Terry J. Higgins, Rob Roy MacGregor, Pablo Tebas, Jean D. Boyer, Kenneth E. Ugen
Publikováno v:
Vaccine. 23:2066-2073
Antiviral therapy prolongs suppression of viral replication and allows for significant immune reconstitution but has not been effective in eradicating reservoirs of virus, which produce resurgent viremia when highly active antiretroviral therapy (HAA
Autor:
Jean D. Boyer, Kenneth E. Ugen, David B. Weiner, Richard B. Ciccarelli, Michael A. Chattergoon, Yaela Baine, Rob Roy MacGregor, Richard S. Ginsberg, Leslie R. Coney, Kim Lacy, Mark L. Bagarazzi, Terry J. Higgins, Stephen J. Gluckman
Publikováno v:
Journal of Infectious Diseases. 178:92-100
A DNA-based vaccine containing human immunodeficiency virus type 1 (HIV-1) env and rev genes was tested for safety and host immune response in 15 asymptomatic HIV-infected patients who were not using antiviral drugs and who had CD4+ lymphocyte counts
Autor:
Richard Haubrich, Paul S. Lietman, Carla P. Pettinelli, Martin S. Hirsch, Richman Dd, Richard S. Ginsberg, Stephen A. Spector, Michael M. Lederman, Charles Flexner, Fayez M. Hamzeh
Publikováno v:
Journal of Infectious Diseases. 172:1246-1252
Ro 24-7429, a Tat antagonist, dosed at 75, 150, or 300 mg/day, was compared with nucleoside analogue (zidovudine or didanosine) for 12 weeks in 96 human immunodeficiency virus (HIV)-infected patients to assess safety and activity. The primary adverse
Autor:
Richard S. Ginsberg, Lawrence D. Mayer, Marcel B. Bally, Linda C.L. Tai, George N. Mitilenes, Pieter R. Cullis
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Biomembranes. 1025:143-151
Studies from this laboratory (Mayer et al. (1986) Biochim. Biophys. Acta 857, 123-126) have shown that doxorubicin can be accumulated into liposomal systems in response to transmembrane pH gradients (inside acidic). Here, detailed characterizations o
Publikováno v:
Journal of Liposome Research. 1:481-490
To present data on a continuing phase I study of liposomal doxorubicin at this time may seem like a giant leap backwards. Liposomally encapsulated doxorubicin has been available for clinical use for some years. Phase I studies have been completed, an
Autor:
Mark Pian, T. D. Murphy, David M. Orenstein, Christopher M. Oermann, R. Fink, John Stevens, J. Finder, John L. Colombo, C. Ren, Michael J. Light, Ruth McBride, Jack D. Gorvoy, Carlos Milla, C. Prestige, Robert G. Castile, Karen McCoy, D. Stokes, Glenna Winnie, C. Harris, K. Voter, Geoffrey Kurland, Alan M. Jewell, Susanna A. McColley, Laurie Varlotta, Warren E. Regelmann, Peter Hiatt, Michael Bowman, Melisa A. Palacio, Drucy Borowitz, Richard S. Ginsberg, Jay D. Eisenberg, Nicole Hamblett, M. Dyson, Pedro A. Piedra, Stanley G. Cron, Paul H. Sammut, M. E. Brown
Publikováno v:
Vaccine. 21(19-20)
A third generation, purified fusion protein (PFP-3) vaccine was developed to prevent severe respiratory syncytial virus (RSV) disease in high-risk groups. A phase II, multi-center, adjuvant-controlled trial was performed in RSV seropositive children
Autor:
Xin Tu, Christina U Kang, Yaela Baine, David B. Weiner, Richard S. Ginsberg, Terry J. Higgins, Jean D. Boyer, Kenneth E. Ugen, Rob Roy MacGregor
Publikováno v:
AIDS (London, England). 16(16)
Objective An effective HIV-1 vaccine will likely need to induce strong cell-mediated immunity in humans. Therefore, we examined the ability of a DNA HIV-1 vaccine to induce a T-cell response in HIV-1 seronegative humans. Design Individuals were enrol
Autor:
Lois Ahn, Jean D. Boyer, Suzanne Vogt, Mark L. Bagarazzi, Rob Roy MacGregor, Terry J. Higgins, Kristen Schumann, Brett Nath, David B. Weiner, Richard B. Ciccarelli, Yaela Baine, Kim Lacy, Richard S. Ginsberg, Adam D. Cohen
Publikováno v:
The Journal of infectious diseases. 181(2)
There is a pressing need to test novel vaccine concepts in an effort to develop an effective vaccine for human immunodeficiency virus (HIV) type 1. A phase I clinical study was done to test the immunogenicity of an HIV env/rev DNA vaccine, which was
Autor:
David B. Weiner, Richard B. Ciccarelli, Mark L. Bagarazzi, Kristen Schumann, Jean D. Boyer, Kenneth E. Ugen, Rob Roy MacGregor, Richard S. Ginsberg, Adam D. Cohen, Ali Javadian, Kim Lacy, Lois Ahn, Jong Kim
Publikováno v:
Vaccine. 17
DNA vaccines have a demonstrated ability to induce humoral and cellular immune responses in animal models and humans. The technology, although it dates back to the 1950's, has had an insurgence of interest within the past few years following concurre